G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is currently advancing three clinical-stage oncology programs. Two of our product candidates, trilaciclib and lerociclib, have broad therapeutic potential and may serve as backbone therapies for multiple combination regimens. Our third product candidate, G1T48, is a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of estrogen receptor-positive (ER+) breast cancer. All three investigational therapies have the potential to become new standards of care for women living with breast cancer and provide benefit at early stages of their disease, including in the adjuvant setting. G1 owns or holds an exclusive license for worldwide commercial rights to each of its product candidates. Source
No articles found.
Five Star Senior Living Inc. is a senior living and healthcare services company. A...
Five Star Senior Living Inc. is a senior living...
AzurRx BioPharma is a development stage biopharmaceutical company (NASDAQ: AZRX) f...
AzurRx BioPharma is a development stage biophar...
Itamar Medical Ltd. is a publicly traded medical device company (TASE:ITMR) based ...
Itamar Medical Ltd. is a publicly traded medica...
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel pr...
Novavax, Inc. is a clinical-stage vaccine compa...
We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a n...
We are a clinical stage biopharmaceutical compa...
aTyrâs mission is to translate newly discovered biological pathways to develop i...
aTyrâs mission is to translate newly discover...
Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnolog...
Founded in 2009, Clovis Oncology (NASDAQ: CLVS)...
Join the National Investor Network and get the latest information with your interests in mind.